Pheast Therapeutics has begun a phase 1 trial for PHST001, targeting CD24 in advanced solid tumors, to evaluate safety and determine the phase 2 dose. PHST001 has shown promising preclinical results, ...

GT-008 is a first-in-class, glycan-dependent monoclonal antibody targeting CD24, a surface protein implicated in tumor progression. By recognizing a tumor-associated O-glycoform of CD24—limited in ...

The biotech set aside a further 10% of its IPO haul for a planned trial of anti-CD24 antibody IMM47. ImmuneOnco revealed (PDF) a shift in its plan after the Hong Kong stock market closed Tuesday.

In 2009, OncoImmune’s founders identified a signal transducer molecule, CD24, which suppresses inflammation by binding to a pattern recognition receptor called Siglec10. They further determined ...

EQS-News: Pentixapharm Holding AG / Key word(s): Conference/Scientific publication Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 25.04. ...